SuperworthAmneal Pharmaceuticals EPS AMRX
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- $0.49
- Latest quarter, Q2 FY26
- $0.18
- +157% on a year earlier
- Fiscal year 2025
- $0.23
Amneal Pharmaceuticals' earnings per share was $0.49 over the twelve months to Jun 30, 2026, up 4800% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.18, up 157% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 18% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.23 | n/a |
| FY2024 | −$0.38 | n/a |
| FY2023 | −$0.31 | n/a |
| FY2022 | −$0.86 | −1329% |
| FY2021 | $0.07 | −89% |
| FY2020 | $0.62 | n/a |
| FY2019 | −$2.76 | n/a |
| FY2018 | −$0.17 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.18 | +157% | $0.49 | |
| Q1 FY26 | $0.19 | +375% | $0.38 | |
| Q4 FY25 | $0.11 | n/a | $0.23 | |
| Q3 FY25 | $0.01 | n/a | $0.02 | |
| Q2 FY25 | $0.07 | +250% | $0.01 | |
| Q1 FY25 | $0.04 | n/a | −$0.04 | |
| Q4 FY24 | −$0.10 | n/a | −$0.38 | |
| Q3 FY24 | $0.00 | −100% | −$0.68 | |
| Q2 FY24 | $0.02 | −75% | −$0.62 | |
| Q1 FY24 | −$0.30 | n/a | −$0.56 | |
| Q4 FY23 | −$0.40 | n/a | −$0.31 | |
| Q3 FY23 | $0.06 | n/a | $0.06 |
Against its peers
Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| LQDALiquidia | $1.39 | |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Amneal Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.